These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32030214)

  • 1. Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.
    Saito Y; Horiuchi S; Morooka H; Ibi T; Takahashi N; Ikeya T; Shimizu Y; Hoshi E
    J Thorac Dis; 2019 Dec; 11(12):4982-4991. PubMed ID: 32030214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
    PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay.
    Grote HJ; Feng Z; Schlichting M; Helwig C; Ruisi M; Jin H; Scheuenpflug J; Gann CN; Su Z; Reck M; Vokes EE; Kerr KM
    J Thorac Oncol; 2020 Aug; 15(8):1306-1316. PubMed ID: 32353599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
    Batenchuk C; Albitar M; Zerba K; Sudarsanam S; Chizhevsky V; Jin C; Burns V
    J Clin Pathol; 2018 Dec; 71(12):1078-1083. PubMed ID: 30275099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
    Skov BG
    Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):49-55. PubMed ID: 31913160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer.
    Hwang DM; Albaqer T; Santiago RC; Weiss J; Tanguay J; Cabanero M; Leung Y; Pal P; Khan Z; Lau SCM; Sacher A; Torlakovic E; Cheung C; Tsao MS
    J Thorac Oncol; 2021 Sep; 16(9):1490-1500. PubMed ID: 33915250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer.
    Song L; Zeng L; Yan H; Xu Q; Xia Q; Lei J; Chen X; Hu X; Wang Z; Liu H; Yang N; Zhang Y
    Commun Med (Lond); 2022 Nov; 2(1):137. PubMed ID: 36352254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.
    Ahn S; Kim KM
    Mod Pathol; 2021 Sep; 34(9):1719-1727. PubMed ID: 34002009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
    Wang H; Agulnik J; Kasymjanova G; Fiset PO; Camilleri-Broet S; Redpath M; Cohen V; Small D; Pepe C; Sakr L; Spatz A
    Lung Cancer; 2019 Jun; 132():36-38. PubMed ID: 31097091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples.
    Zhang W; Cao Z; Gao C; Huang Y; Wu C; Zhang L; Hou L
    Transl Cancer Res; 2020 Oct; 9(10):5819-5828. PubMed ID: 35117196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
    Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
    Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study.
    Russell PA; Farrall AL; Prabhakaran S; Asadi K; Barrett W; Cooper C; Cooper W; Cotton S; Duhig E; Egan M; Fox S; Godbolt D; Gupta S; Hassan A; Leslie C; Leong T; Moffat D; Qiu MR; Sivasubramaniam V; Skerman J; Snell C; Walsh M; Whale K; Klebe S
    Pathology; 2023 Dec; 55(7):922-928. PubMed ID: 37833206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance between four PD-L1 immunohistochemical assays and 22C3 pharmDx assay in esophageal squamous cell carcinoma in a multicenter study.
    Xue L; Li Y; Jiang L; Liu C; Cheng N; Guo C; Jin Y; Zhou P; Xue X; Wang Y; Wang W; Liu Y; Ying J
    J Natl Cancer Cent; 2024 Jun; 4(2):162-168. PubMed ID: 39282585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.
    Kalpakoff M; Hund S; Musser J; Roach C; Apostolaki A; Vilardo M; Peltz L; Watts B; LaPlaca C; Tabuena-Frolli S; DiMaio MA; Welcher R; Kulangara K
    Appl Immunohistochem Mol Morphol; 2021 Oct; 29(9):667-673. PubMed ID: 33973887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience.
    Takeda M; Kasai T; Naito M; Tamiya A; Taniguchi Y; Saijo N; Naoki Y; Okishio K; Shimizu S; Kojima K; Nagoya A; Sakamoto T; Utsumi T; Yoon HE; Matsumura A; Atagi S
    Clin Med Insights Oncol; 2019; 13():1179554918821314. PubMed ID: 30670923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
    Zhou C; Srivastava MK; Xu H; Felip E; Wakelee H; Altorki N; Reck M; Liersch R; Kryzhanivska A; Oizumi S; Tanaka H; Hamm J; McCune SL; Bennett E; Gitlitz B; McNally V; Ballinger M; McCleland M; Zou W; Das Thakur M; Novello S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37903590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.